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Abstract. 
 
The receptor tyrosine kinase p185
 
c-neu
 
 can be 
constitutively activated by the transmembrane domain 
 
mutation Val
 
664
 
®
 
Glu, found in the oncogenic mutant 
p185
 
neu
 
. This mutation is predicted to allow intermolec-
ular hydrogen bonding and receptor dimerization. Un-
derstanding the activation of p185
 
c-neu
 
 has assumed 
greater relevance with the recent observation that 
achondroplasia, the most common genetic form of hu-
man dwarfism, is caused by a similar transmembrane 
domain mutation that activates fibroblast growth factor 
receptor (FGFR) 3. We have isolated novel transform-
ing derivatives of p185
 
c-neu
 
 using a large pool of degen-
erate oligonucleotides encoding variants of the trans-
membrane domain. Several of the transforming isolates 
identified were unusual in that they lacked a Glu at res-
idue 664, and others were unique in that they contained 
multiple Glu residues within the transmembrane do-
main. The Glu residues in the transforming isolates of-
ten exhibited a spacing of seven residues or occurred in 
positions likely to represent the helical interface. How-
ever, the distinction between the sequences of the 
transforming clones and the nontransforming clones 
did not suggest clear rules for predicting which specific 
sequences would result in receptor activation and trans-
formation. To investigate these requirements further, 
entirely novel transmembrane sequences were con-
structed based on tandem repeats of simple heptad se-
quences. Activation was achieved by transmembrane 
sequences such as [VVVEVVA]
 
n
 
 or [VVVEVVV]
 
n
 
, 
whereas activation was not achieved by a transmem-
brane domain consisting only of Val residues. In the 
context of these transmembrane domains, Glu or Gln 
were equally activating, while Lys, Ser, and Asp were 
not. Using transmembrane domains with two Glu resi-
dues, the spacing between these was systematically var-
ied from two to eight residues, with only the heptad 
spacing resulting in receptor activation. These results 
are discussed in the context of activating mutations in 
the transmembrane domain of FGFR3 that are respon-
sible for the human developmental syndromes achon-
droplasia and acanthosis nigricans with Crouzon Syn-
drome.
 
T
 
he
 
 
 
neu
 
 oncogene was initially isolated from a rat
ethylnitrosourea-induced neuro/glioblastoma and en-
codes a receptor tyrosine kinase belonging to the
epidermal growth factor receptor (EGFR)
 
1
 
 family; the on-
cogenic mutant, referred to as p185
 
neu
 
, is closely related to
its wild-type cellular homologue, referred to as p185
 
c-neu
 
(Shih et al., 1981; Schechter et al., 1984; Bargmann et al.,
1986
 
a
 
, 
 
b
 
; Dougall et al., 1994). Like other members of the
EGFR family, p185
 
c-neu
 
 consists of an extracellular ligand-
binding domain, a transmembrane domain, and an intra-
cellular tyrosine kinase domain (Drebin et al., 1984; Ull-
rich and Schlessinger, 1990). As for other receptor tyrosine
kinases, ligand binding to the wild-type p185
 
c-neu
 
 receptor
induces receptor dimerization, leading to tyrosine kinase
activation and subsequent downstream signaling events
(Peles et al., 1991; Dougall et al., 1994; Stein et al., 1994;
for review see Heldin, 1995).
Activation of p185
 
c-neu
 
 arises from structural changes,
such as the Val
 
664
 
®
 
Glu mutation in the transmembrane
domain (Bargmann et al., 1986
 
b
 
) or deletions in the extra-
cellular juxtamembrane region (Siegel et al., 1994). Acti-
vated p185
 
neu
 
 resembles a ligand-stimulated receptor, as evi-
denced by its increased tyrosine phosphorylation of other
proteins, as well as elevated levels of autophosphorylation
(Bargmann and Weinberg, 1988
 
a
 
; Segatto et al., 1988;
Stern et al., 1988; Weiner et al., 1989
 
a
 
; Peles et al., 1991;
Ben-Levy et al., 1992; Cao et al., 1992; Qian et al., 1995).
In addition, p185
 
neu
 
 is primarily found in an aggregated
form while wild-type p185
 
c-neu
 
 is monomeric (Weiner et
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1. 
 
Abbreviations used in this paper
 
: BPV, bovine papilloma virus; ECL,
enhanced chemiluminescence; EGFR, epidermal growth factor receptor;
FGFR, fibroblast growth factor receptor; TCR
 
a
 
, T cell receptor 
 
a
 
 chain.
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al., 1989
 
b
 
). The mutation Val
 
664
 
®
 
Glu may facilitate
dimerization by allowing intermolecular hydrogen bond-
ing between the side chain of Glu
 
664
 
 in one receptor and
the carbonyl oxygen of Ala
 
661
 
 in another receptor, thereby
stabilizing the interaction between the two 
 
a
 
-helical trans-
membrane domains (Sternberg and Gullick, 1989). In the
initial characterization of p185
 
neu
 
, various mutations at
Val
 
664
 
 were examined. Both Glu and Gln were found to be
equally activating for transformation, with other potential
hydrogen bond-forming residues such as Asp and Tyr ex-
hibiting low activity (Bargmann and Weinberg, 1988
 
b
 
).
Prior mutagenesis studies have suggested that the pri-
mary structure in the vicinity of Glu
 
664
 
 must play a signifi-
cant role in activation of p185
 
neu
 
. For example, substitu-
tion of Glu at the neighboring positions 663 or 665 does
not result in activation (Bargmann and Weinberg, 1988
 
b
 
).
The importance of the subdomain surrounding Glu
 
664
 
 has
been further examined by the mutations Val
 
663
 
®
 
Gly and
Gly
 
665
 
®
 
Val, which both abolished transforming activity
(Cao et al., 1992). This study also found that the lateral po-
sition and rotational orientation of Glu in the transmem-
brane domain did not correlate with transformation.
A subdomain containing a loosely defined sequence mo-
tif has been noted in the transmembrane domains of many
other receptor tyrosine kinases (Sternberg and Gullick,
1990). This motif consists of a five-residue segment: posi-
tion 0 (P0), corresponding to Ala
 
661
 
 in p185
 
c-neu
 
, exhibits a
small side chain such as Gly, Ala, Ser, or Thr; position P3
displays an aliphatic side chain like Ala, Val, Leu, or Ile,
but is occupied by Glu
 
664
 
 in activated p185
 
neu
 
; and position
P4 exhibits either Gly or Ala. The presence of this motif in
many different receptor tyrosine kinases suggests an im-
portant role in facilitating ligand-induced receptor dimer-
ization.
For many years, p185
 
neu
 
 represented the sole example of
a receptor tyrosine kinase that is activated by mutation
within its transmembrane domain. Recently, however, it
has become clear that some human developmental abnor-
malities are due to transmembrane domain mutations in
fibroblast growth factor receptor (FGFR) 3. Achondropla-
sia, the most common genetic form of human dwarfism,
results from a single amino acid change in the transmem-
brane domain of FGFR3, Gly
 
380
 
®
 
Arg (Rousseau et al.,
1994; Shiang et al., 1994). As shown in work from this lab-
oratory, this mutation results in constitutive activation of
FGFR3, not unlike the constitutive activation of p185
 
neu
 
by the mutation Val
 
664
 
®
 
Glu (Webster and Donoghue,
1996). Achondroplasia is not the only developmental syn-
drome arising from transmembrane domain mutations in
FGFR3, as Meyers et al. (1995) recently identified a novel
substitution mutation in FGFR3 that is responsible for two
distinct developmental syndromes: acanthosis nigricans in
association with Crouzon Syndrome. The existence of these
human developmental abnormalities arising from activat-
ing mutations in the transmembrane domain of a receptor
tyrosine kinase suggests that the paradigm of receptor ac-
tivation provided by p185
 
neu
 
 is relevant to human disease
and well worth probing in molecular detail.
In this study, we have used pools of long oligonucle-
otides encoding the p185
 
c-neu
 
 transmembrane domain to
target degeneracies to specific positions. This represents a
powerful approach for the simultaneous mutation of mul-
 
tiple residues, facilitating the isolation of transforming and
nontransforming clones from a large pool of different mu-
tants. In an effort to understand the differences between
the transforming and nontransforming clones, we con-
structed completely novel transmembrane domains and
demonstrated that some of these, such as a tandem repeat
of [VVVEVVV]
 
n
 
, are able to induce efficient receptor ac-
tivation as evidenced by transformation of NIH3T3 cells.
These results demonstrate that an apparently complex
transmembrane domain can be substituted by simple se-
quences of repeated residues, provided that amino acids
capable of hydrogen bonding, such as Glu or Gln, are in-
cluded at appropriate positions. Significantly, receptor ac-
tivation by the tandem repeats is accomplished without
any specific sequence contribution from the native p185
 
c-neu
 
transmembrane domain. The experiments described here
provide a basis for understanding the role of the trans-
membrane domain in the activation of p185
 
neu
 
, or for the
activation of other receptor tyrosine kinases such as
FGFR3.
 
Materials and Methods
 
Construction of Degenerate Pools and
Additional Mutants
 
Oligonucleotides were synthesized encoding the p185
 
c-neu
 
 transmembrane
domain with degenerate codons targeted to the presumptive 
 
a
 
-helical po-
sitions designated “a,” “d,” and “e,” shown in Fig. 1. In Pool 1, codons for
Val, Ala, Gly, and Glu were targeted to each of these positions. In Pool 2,
the codons for Val, Ala, or Gly, but not Glu, were targeted to these posi-
tions. The degenerate oligonucleotides were synthesized on an oligonucle-
otide synthesizer (Appiled Biosystems Inc., Foster City, CA) and then
amplified by PCR. The degenerate pools were ligated into a pSV2-derived
vector encoding p185
 
c-neu
 
 (pSV2
 
neu
 
NheI/SacI), replacing the wild-type
transmembrane domain at silent NheI and SacI restriction sites (Webster
and Donoghue, 1996). The NheI site corresponds to bases 1973–1978, and
the SacI site corresponds to bases 2114–2119, in the published nucleotide
sequence encoding p185
 
c-neu
 
 (Bargmann et al., 1986
 
a
 
).
The synthetic oligonucleotide sequence used to generate the degener-
ate pools is shown below. Silent restriction sites for NheI (GCTAGC) and
SacI (GAGCTC) embedded within the sequence are shown in bold. Extra
residues were added at both ends to facilitate restriction digestion of the
PCR-amplified double-stranded product. The first and last triplet codons
shown correspond to Ala
 
653
 
 (GCT of NheI site) and Leu
 
701
 
 (CTC of SacI
site), respectively, in the published amino acid sequence of p185
 
c-neu
 
(Bargmann et al., 1986
 
a
 
): 5
 
9
 
-GCAGAGA.
 
GCT.AGC.
 
CCG.GTG.ACA.
TTC.ATC.ATT.GXA.ACT.GTA.GXA.GXA.GTC.CTG.GXA.TTC.CTG.
GXA.GXA.GTG.GTG.GXA.GTT.GGA.GXA.GXA.ATC.AAA.CGA.
AGG.AGA.CAG.AAG.ATC.CGG.AAG.TAT.ACG.ATG.CGT.AGG.
CTG.CTG.CAG.GAA.ACT.
 
GAG.CTC.
 
GTGGAGCC
 
2
 
3
 
9
 
. Degeneracies
were encoded as follows: for Pool 1, X 
 
5
 
 A, G, C, or T; and for Pool 2, X
 
5
 
 G, C, or T. The pools of single-stranded degenerate oligonucleotides
were PCR amplified using standard conditions with the following primers:
a sense strand primer, corresponding to the 5
 
9
 
-end of the degenerate oli-
gonucleotide sequence shown above and spanning the NheI site, 5
 
9
 
-GCA-
GAGAGCTAGCCCGGTGAC-3
 
9
 
; and an antisense strand primer,
corresponding to the complement of the 3
 
9
 
-end of the degenerate oligonu-
cleotide sequence shown above and spanning the SacI site, 5
 
9
 
-GGCTC-
CACGAGCTCAGTTTCC-3
 
9
 
.
Additional mutants described in the text were constructed by synthe-
sizing pairs of single-stranded oligonucleotides to create double-stranded
DNA fragments with NheI and SacI cohesive overhangs, for ligation into
pSV2
 
neu
 
NheI/SacI (Webster and Donoghue, 1996).
 
Focus Assays
 
NIH3T3 cells were transfected using a modified calcium phosphate trans-
fection protocol (Chen and Okayama, 1987), as described previously (Ma-
her et al., 1993). Transfection frequencies were determined by cotransfect- 
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ing with 0.1 
 
m
 
g of pSV2
 
neo
 
, and half of the cells were subsequently split
into media containing G418 (Maher et al., 1993). For each DNA sample,
the number of foci was normalized with respect to the number of 
 
Neo
 
-
resistant colonies and then expressed as a percentage of the transforma-
tion efficiency obtained with pSV2
 
neu
 
NT, encoding p185
 
neu
 
 with the mu-
tation Val
 
664
 
®
 
Glu. All mutants were assayed at least three times in inde-
pendent experiments for transformation efficiency.
 
Isolation of Transmembrane Domains from
Degenerate Pools
 
At 9 d after transfection of degenerate Pool 1 into NIH3T3 cells, individ-
ual foci of transformed cells were expanded and RNA was isolated.
cDNA was prepared using the following primer: 5
 
9
 
-ATACGCTTCA-
TCTAGAATTTCTTTG-3
 
9
 
, complementary to bases 2323–2347 in the
published nucleotide sequence encoding p185
 
c-neu
 
 (Bargmann et al., 1986
 
a
 
).
This cDNA was used for PCR with primers described above, and the
products digested with NheI and SacI. For the mutants designated DEG.1
through DEG.5, each recovered transmembrane domain was ligated into
pSV2
 
neu
 
NheI/SacI and sequenced, and its ability to activate p185
 
c-neu
 
 to a
transforming phenotype was reconfirmed by transfection into NIH3T3
cells. This protocol ensured that transformation was due to a unique se-
quence, containing a single transmembrane domain, rather than a mixture
of sequences. The nontransforming isolates, DEG.6 through DEG.10,
were recovered in the same way but were negative for NIH3T3 transfor-
mation when assayed as individual clones.
 
Indirect Immunofluorescence
 
Transiently transfected Cos-1 cells (Chen and Okayama, 1987) were fixed
in 3% paraformaldehyde/PBS for 10 min and then permeabilized in 0.5%
Triton X-100/PBS for 5 min (Lee and Donoghue, 1992). Cells were incu-
bated with mouse monoclonal antibody 7.16.4 to an extracellular epitope
of p185
 
c-neu
 
 (c-
 
neu
 
 [AB-4] clone 7.16.4 from Oncogene Science Inc., Man-
hasset, NY) followed by FITC-conjugated goat anti–mouse antiserum
(Boehringer Mannheim Corp., Indianapolis, IN). To detect cell surface
expression of p185
 
c-neu
 
 and derivatives, cells were fixed with paraformal-
dehyde and incubated without permeabilization, as described previously
(Hannink and Donoghue, 1986; Lee and Donoghue, 1992).
For double-label experiments to detect both intracellular and cell sur-
face expression, cells were fixed as described above and then treated with
mouse mAb 7.16.4 (1:50 dilution) against an extracellular epitope of
p185
 
c-neu
 
, followed by FITC-conjugated goat anti–mouse antiserum (Boeh-
ringer Mannheim Corp.) at 1:1,500 dilution. The same cells were then per-
meabilized with 1% Triton X-100/PBS and treated with a rabbit poly-
clonal p185
 
c-neu
 
 C-18 antibody (Santa Cruz Biotechnology, Santa Cruz,
CA) at 1:3,000 dilution, which was detected with rhodamine-conjugated
goat anti–rabbit antiserum (Boehringer Mannheim Corp.) at 1:4,000 dilu-
tion.
 
Immunoprecipitation, In Vitro Kinase, and 
Dimerization Assays
 
Cos-1 cells were split at a density of 
 
z
 
2 
 
3
 
 10
 
5
 
 cells per 60-mm plate and
transfected with 10 
 
m
 
g of DNA the next day (Chen and Okayama, 1987).
After 2 d, the transfected cells were labeled for 
 
z
 
7 h with 100 
 
m
 
Ci of
[
 
35
 
S]Cys and [
 
35
 
S]Met each per ml in DME lacking Cys and Met. The cells
were rinsed with TS buffer and lysed in 0.5 ml NP-40 lysis buffer (20 mM
Tris, pH 7.5, 137 mM NaCl, 1% NP-40, 1 mM sodium orthovanadate, 5 mM
EDTA, 10 
 
m
 
g/ml aprotinin, 10% glycerol), and clarified lysates were pre-
pared (Maher et al., 1993). Immunoprecipitation was carried out using
mAb 7.16.4, and immune complexes were collected with protein A–Sepha-
rose beads. After immunoprecipitation, the Sepharose beads were washed
in NP-40 lysis buffer, and the samples were split in half. Samples for the
kinase assay were washed twice in kinase buffer (20 mM Tris, pH 7.5, 10 mM
MnCl
 
2
 
, 5 mM MgCl
 
2
 
), resuspended in 20 
 
m
 
l kinase buffer containing 10
 
m
 
Ci 
 
g
 
-[
 
32
 
P]ATP, incubated at room temperature for 10 min, washed twice
with NP-40 lysis buffer, and analyzed by 7.5% SDS-PAGE and autora-
diography. The other half of the samples was analyzed by 7.5% SDS-
PAGE, and the 
 
35
 
S-labeled proteins were visualized by fluorography.
To examine dimerization, transfected cells were lysed in RIPA (10 mM
sodium phosphate, pH 7.0, 1% Triton X-100, 0.1% SDS, 1% DOC, 150
mM NaCl, 2 mM EDTA, 50 mM NaF, 1% aprotinin, 1 mM sodium ortho-
vanadate, 100 
 
m
 
M PMSF, and 10 mM iodoacetamide) and immunoprecip-
itated as described above. 2
 
3
 
 nonreducing sample buffer (4% SDS, 10 mM
sodium phosphate, pH 7.0, 20% glycerol, 0.08% bromophenol blue) was
added to the protein A–Sepharose beads and then boiled. For the reduc-
ing samples, an aliquot was removed and 2-mercaptoethanol was added to
0.7 M and DTT was added to 20 mM. Samples were boiled again and run
on a 4–12% gradient gel. Proteins were then transferred to nitrocellulose,
blotted with a rabbit polyclonal p185
 
c-neu
 
 C-18 antiserum, and detected by
enhanced chemiluminescence (ECL).
To examine phosphotyrosine incorporation in immunoprecipitated re-
ceptors, reduced samples prepared as above were run on a 4–12% gradi-
ent gel, transferred to nitrocellulose, blotted with mouse antiphosphoty-
rosine mAb 4G10 (Upstate Biotechnology, Inc., Lake Placid, NY) and
detected by ECL. The membrane was then reprobed with polyclonal
p185
 
c-neu
 
 C-18 antiserum to examine receptor expression, which was again
detected by ECL.
 
Results
 
Pools of Mutants with Degenerate
Transmembrane Domains
 
The model proposed by Sternberg and Gullick (1989) pos-
tulated the transmembrane domain of p185
 
neu
 
 as an 
 
a
 
-heli-
cal sequence in which Glu664 promotes activation by creat-
ing a hydrogen bond between two receptor molecules. To
further characterize these interactions, we constructed
pools of degenerate oligonucleotides that permitted vari-
ability in the transmembrane domain at positions P0, P3,
and P4 in the Sternberg and Gullick notation, which are
predicted to be of greatest structural importance based on
a comparison of transmembrane domains from many
growth factor receptors (Sternberg and Gullick, 1990). The
repeating heptad motif present in interacting a-helical do-
mains can also be designated (abcdefg)n, in which the “a”
and “d” positions are occupied by the residues at the inter-
face where the two a-helical domains interact.
In degenerate Pool 1 (Fig. 1 B), we randomly targeted
codons for Val, Ala, Gly, or Glu to heptad positions “a,”
“d,” and “e.” This choice allowed us to examine the poten-
tial effects of multiple Glu residues targeted to a variety of
positions. The pool of degenerate oligonucleotides was
amplified by PCR and then ligated into a pSV2-derived
vector encoding p185c-neu (pSV2neuNheI/SacI), replacing
the wild-type transmembrane domain. The DNA was trans-
fected into NIH3T3 cells, and the resulting foci were ex-
panded. Subsequently, to recover individual transmem-
brane domains from foci of transformed cells, RNA was
prepared from expanded cells and subjected to reverse
transcriptase–PCR as described in Materials and Methods,
and the resulting sequences were then subcloned as unique
plasmids. Individual transmembrane domains recovered
in this fashion were next ligated back into pSV2neuNheI/
SacI and reassayed for transformation of NIH3T3 cells.
This ensured that transformation would be due to a
unique sequence, rather than a mixture of transmembrane
sequences.
The sequences of the transforming mutants isolated
from this pool, designated DEG.1 through DEG.5 (Fig.
1 C), were completely distinct in comparison with other
mutants previously described. Interestingly, none of the
activated mutants except DEG.1 exhibited a Glu at resi-
due 664. Moreover, all of these mutants, except for
DEG.2, exhibited multiple Glu residues spaced at inter-
vals of seven residues, or multiples of seven residues.
These results were intriguing considering that Glu resi-The Journal of Cell Biology, Volume 137, 1997 622
dues are rare in hydrophobic transmembrane domains.
These transforming isolates provided clear evidence that
multiple Glu residues do not disrupt the ability of the
transmembrane domain to insert properly into the mem-
brane.
Approximately 15 nontransforming mutants were also
isolated from Pool 1, five of which, DEG.6 through
DEG.10, are described in Fig. 1 D. The distinctions be-
tween the transforming and nontransforming isolates were
not entirely obvious. Double-label indirect immunofluo-
rescence was used to determine whether the lack of trans-
forming activity of these mutants might reflect an abnor-
mal subcellular localization. This was accomplished by using
an antibody against an extracellular epitope to detect sur-
face expression in cells before permeabilization, followed
by a second antibody against the COOH terminus to de-
tect intracellular expression in the same cell after perme-
abilization (Fig. 2). Fig. 2 B shows the immunofluores-
cence observed for control cells under identical conditions,
with mock-transfected cells negative for both intracellular
and surface staining (Fig. 2 B, A and B), whereas cells ex-
pressing p185neu exhibit readily detectable staining both
intracellularly and also at the cell surface (Fig. 2 B, C and
D). As shown in Fig. 2 A, the mutants DEG.7, DEG.9, and
DEG.10 were expressed intracellularly but failed to reach
the cell surface (Fig. 2 A, D, H, and J), suggesting that their
lack of biological activity might be due to aggregation or
interaction with some component of the ER/Golgi. In con-
trast, the mutants DEG.6 and DEG.8 were expressed at
the cell surface (Fig. 2 A, B and F), suggesting that their
transmembrane domains fail to activate these receptors,
despite localizing normally to the plasma membrane.
Importantly, no transforming mutants were isolated
from degenerate Pool 2 (Fig. 1 B), in which Val, Ala, or
Gly, but not Glu, were targeted to heptad positions “a,”
“d,” and “e.” Clearly, the presence of Glu residues, which
can potentially satisfy a requirement for hydrogen bond-
ing, is a key element in receptor activation.
Design of Transmembrane Domains with Consensus 
Heptad Repeats
The transmembrane domains of the transforming mutants
DEG.1–DEG.5 suggested that there are many allowed
positions for Glu residues, yet the distinction between
these sequences and those of the nontransforming mutants
DEG.6–DEG.10 did not suggest clear rules for predicting
which specific sequences will result in receptor activation
and transformation. We therefore designed simple consen-
sus repeats, containing a centrally located Glu residue, with
most of the other residues substituted by Val, such as
[VVVEVVA]n, [VVVEVVG]n, [VVVEVVV]n, or [AVV-
EGVL]n (designated CONS.A, CONS.B, CONS.C, and
CONS.D, respectively). Mutants were then constructed
with the transmembrane domain composed entirely of
these consensus sequences, repeated over the entire trans-
membrane domain of z25 residues. Surprisingly, these
constructs were transforming, with the CONS.A and
CONS.D constructs exhibiting the greatest activity (Fig.
3 B). These results suggest that these simple repeating se-
quences contain all the information necessary for receptor
activation. Evidently, there is little sequence specificity
Figure 1. Isolates recovered from pools with degenerate trans-
membrane domains. (A) The sequences of wild-type p185c-neu
and oncogenic p185neu (with the mutation Val664®Glu) are
shown. The locations of the presumptive heptad repeats of the
transmembrane region are shown, along with the letters indicat-
ing the heptad positions. Vertical lines designate the probable
borders of the transmembrane domain. The activating Glu resi-
due of p185neu is boldfaced. The five-residue sequence motif
found in many receptor tyrosine kinase transmembrane domains
(Sternberg and Gullick, 1990), referred to as P0-P4, corresponds
to residues 661–665. The location of P0 and P3 are shown. (B)
Oligonucleotides coding for degenerate transmembrane domains
were synthesized, amplified, and cloned into pSV2neuNheI/SacI
as described in Materials and Methods. In the first pool of degen-
erate oligos, codons for either Ala, Val, Gly, or Glu were ran-
domly targeted to the “a,” “d,” and “e” positions. In Pool 2,
codons for Ala, Val, or Gly, but not Glu, were targeted to the
same positions. Asterisks denote the positions at which these de-
generacies were targeted. (C) Pool 1 was transfected into
NIH3T3 cells; individual foci were expanded and used for PCR-
mediated recovery of the unique transmembrane domain present
in each focus. Each recovered transmembrane domain was li-
gated into pSV2neuNheI/SacI to ensure that transformation was
due to a unique transmembrane domain rather than a mixture of
sequences. The sequences of these transforming isolates are
shown, with dashes designating the residues that remained un-
changed from the parent p185c-neu. Glu residues are boldfaced.
(D) For comparison, nontransforming isolates from Pool 1 were
also characterized. The sequences of some of these isolates are
shown. For A, C, and D, transformation by each isolate was
quantitated as a percentage of p185neu. Results represent the av-
erage values from three independent experiments, normalized by
cotransfection with pSV2neo, and presented as follows: 2, 0–5%
of p185neu; 1, 6–40% of p185neu; 11 , 41–100% of p185neu. For B,
transformation by DNA representing the entire pool was re-
corded as follows: 2, 0 foci per 10 mg of DNA; 11, z35 foci per
10 mg of DNA.Chen et al. Transmembrane Sequences for Receptor Activation 623
Figure 2. Immunofluorescence of nontransforming isolates
DEG.6–DEG.10. Double-label indirect immunofluorescence was
used to detect either cell surface expression of p185c-neu-related
proteins (right) or, after permeabilization of cells, intracellular
expression (left). Conditions for the double-label immunofluores-
cence are described in Materials and Methods. (A) (A and B)
mutant DEG.6; (C and D) mutant DEG.7; (E and F) mutant
DEG.8; (G and H) mutant DEG.9; (I and J) mutant DEG.10. (B)
(A and B) Mock transfected cells; (C and D) p185neu. The Journal of Cell Biology, Volume 137, 1997 624
necessary for constitutive activation within the p185neu
transmembrane domain itself.
It was also important to demonstrate that transforma-
tion was due to specific interactions involving Glu resi-
dues. Towards this end, we constructed a derivative of
the CONS.C sequence in which the central Glu of each re-
peat was changed to Val. This mutant transmembrane do-
main, consisting entirely of Val residues, was designated
CONS.CE®V, and was completely devoid of transforming
activity (Fig. 3 B).
Design of Derivative Transmembrane Domains Based 
on Consensus Heptad Repeats
We also tested whether other residues could substitute for
Glu in the context of the CONS.A heptad repeat (Fig. 3 C).
We replaced Glu with Lys, Gln, Ser, and Asp, creating the
mutants CONS.AE®K, CONS.AE®Q, CONS.AE®S, and
CONS.AE®D. These mutants were designed to test whether
other hydrogen-bonding residues could substitute in place
of Glu. Only substitution with Gln allowed significant
transforming activity, whereas Lys, Ser, and Asp were un-
able to activate the receptor. The observation that Gln can
substitute for Glu in the mutant CONS.AE®Q is consistent
with the original characterization of p185neu showing that
Val664®Glu and Val664®Gln were equally effective at acti-
vation (Bargmann and Weinberg, 1988b).
As shown in Fig. 4, A–L, indirect immunofluorescence
demonstrated that most of the mutants exhibited cell sur-
face expression. The ability of these altered receptors to
reach the surface indicates that the mutant transmem-
brane domains did not interfere with the proper localiza-
tion of the protein. The only exception was CONS.AE®D,
which exhibited little or no cell surface staining, even
though the protein is clearly being translated, as shown by
the intracellular staining of permeabilized cells (Fig. 4, O).
However, its reduced surface expression may be due to ag-
gregation or interaction with another protein that is re-
tained in the ER and/or Golgi, as discussed previously for
some of the nontransforming mutants, DEG.7, DEG.9,
and DEG.10.
Spacing and Number of Glu Residues
The design of the degenerate pools of transmembrane do-
mains, as well as the design of the subsequent consensus
repeat clones described above, assumed without any real
evidence that there would exist a fundamental heptad
structural motif resulting from the a-helical transmem-
brane domain. To directly examine this premise, we con-
structed a series of clones in which we varied the spacing
between Glu residues. As the parental clone for this series,
we chose a clone with two Glu residues spaced seven resi-
dues apart in a transmembrane domain composed other-
wise of only Val residues, designated CONS.C2xE. The
spacing between the two Glu residues was then varied
from two to eight residues, as shown in Fig. 5 A. The re-
sults of transformation assays with these clones revealed a
dramatic effect of spacing, with the heptad spacing yield-
ing significantly greater transforming activity than any of
the other clones (Fig. 5 B). When cells expressing these
constructs were examined by indirect immunofluores-
cence, all constructs exhibited cell surface expression (data
not shown), indicating that the lack of transformation was
not due to a defect in surface localization. This experiment
provides compelling evidence for a basic heptad structural
motif in the transmembrane domain of activated forms of
p185c-neu.
Figure 3. Consensus sequences and deriva-
tives. (A) The p185c-neu and p185neu sequences
are shown. The locations of the presumptive
heptad repeats, along with the letters indicat-
ing the heptad positions, are specified. Verti-
cal lines designate the probable borders of
the transmembrane domain. Glu664 is in bold-
face. (B) Consensus sequence mutants were
constructed as described in the text. The
placement of the Glu residues in each mutant
is identical. Based on the variations found in
the transforming isolates from degenerate
Pool 1, the heptad position g in CONS.B and
CONS.C was mutated from Ala in CONS.A
to Gly and Val, respectively. The repeating
heptad in CONS.D is heptad 2 from p185neu
with Thr662 changed to Val. The mutant
CONS.CE®V has a transmembrane domain
composed entirely of Val residues and was
constructed as a negative control. Glu resi-
dues are boldfaced. (C) Derivatives of
CONS.A mutant. Derivatives were designed
in which the Glu residues were substituted by
other residues capable of hydrogen bonding,
such as Lys, Gln, Ser, or Asp. For example,
CONS.AE®Q is identical to CONS.A except that the Glu residues are substituted by Gln. Transformation by each isolate was quanti-
tated as a percentage of p185neu. Results represent the average values from three independent experiments, normalized by cotransfec-
tion with pSV2neo, and presented as 2, 1, or 11 as described in Fig. 1. Surface expression was determined by indirect immunofluores-
cence, as described in text.Chen et al. Transmembrane Sequences for Receptor Activation 625
Figure 4. Indirect immunoflu-
orescence of consensus mu-
tants and derivatives. Indirect
immunofluorescence using the
monoclonal  antibody 7.16.4 di-
rected against the extracellular
region of p185c-neu and a fluo-
rescein-conjugated goat anti–
mouse secondary antibody re-
vealed both cell surface and
intracellular protein expres-
sion.  A–L show nonpermeabi-
lized cells to examine cell sur-
face expression. (A) p185c-neu;
(B) p185neu; (C) CONS.A; (D)
CONS.B; (E) CONS.C; (F)
CONS.D; (G) CONS.AE2; (H)
CONS.AE4; (I) CONS.AE®K;
(J) CONS.AE®Q; (K) CONS.
AE®S; (L) CONS.CE®V. M–O
show cells after permeabiliza-
tion to examine intracellular
expression. (M) p185c-neu; (N)
p185neu; (O) CONS.AE®D.The Journal of Cell Biology, Volume 137, 1997 626
Most of the transforming DEG mutants described ear-
lier contained multiple Glu residues (Fig. 1 C), as did the
transforming mutants CONS.A–CONS.D, which all con-
tained three Glu residues (Fig. 3 B). The occurrence of
multiple Glu residues is in contrast to p185neu, which con-
tains only a single Glu residue in the transmembrane do-
main at position 664. We therefore examined whether
multiple Glu residues are in fact required for activity.
This issue was addressed through two different sets of
mutants, one constructed in the background of CONS.A,
[VVVEVVA], and another set in the background of
CONS.C, [VVVEVVV]. These two sets of mutants yielded
somewhat different results. As shown in Fig. 6 A, “single-
Glu” derivatives of the CONS.A sequences were de-
signed, each possessing only a single Glu residue located at
different positions, and designated CONS.AE2, CONS.AE3,
and CONS.AE4. None of these mutants was transforming,
indicating that within the context of the CONS.A heptad
repeat, a single-Glu residue is not sufficient to provide ac-
tivation. This result is in contrast to the single Glu664 resi-
due that leads to activation of p185neu, suggesting that
there may be sequence information within the transmem-
brane domain, in addition to the Val664®Glu mutation,
that stabilizes dimerization (Cao et al., 1992). We consid-
ered the possibility that these mutant proteins might fail to
reach the cell surface and that this defect might explain
their inactivity in transformation assays. However, all of
the single-Glu proteins were expressed at the cell surface,
as shown by indirect immunofluorescence in Fig. 4, G and
H, for CONS.AE2 and CONS.AE4.
Several mutants were also designed in the CONS.C
background that had either one, two, three, or four Glu
residues, designated CONS.C1xE–CONS.C4xE. The clone
containing three Glu residues, CONS.C3xE, is the original
CONS.C clone. As shown in Fig. 6 B , the mutants with ei-
ther two or four Glu residues, designated CONS.C2xE and
CONS.C4xE, exhibited the greatest activity, almost twice as
much as the mutant with three Glu residues. However, in
this series of mutants, even the presence of a single Glu
residue, as in CONS.C1xE, led to significant transformation
above background.
It is curious that a single Glu residue is activating in the
mutant CONS.C1xE (Fig. 6 B), but not in the very similar
Figure 5. Importance of the spacing of Glu residues. (A) A series
of clones, based on the mutant CONS.C2xE, were constructed
varying the spacing between two Glu residues, from a minimum
spacing of two residues (diad mutant) to a maximum spacing of
eight residues (octad mutant). (B) Transformation by each iso-
late shown in (A) was quantitated as a percentage of p185neu. Nu-
merical results of transformation assays are presented graphically
and represent the average values from two independent experi-
ments, normalized by cotransfection with pSV2neo.
Figure 6. Importance of the number of Glu
residues. (A) Derivatives of CONS.A. Three
derivatives were constructed, each having a
single Glu residue. Depending upon the posi-
tion of the Glu residue, these mutants were
designated CONS.AE2, CONS.AE3, and
CONS.AE4. (B) Derivatives of CONS.C. De-
rivatives were constructed in the background
of CONS.C having from one to four Glu resi-
dues. These clones are designated CONS.C1xE,
CONS.C2xE, CONS.C3xE, and CONS.C4xE.
Note that CONS.C3xE is the parental
CONS.C mutant presented in Fig. 3. Trans-
formation by each isolate was quantitated as
a percentage of p185neu. Results represent the
average values from three independent ex-
periments, normalized by cotransfection with pSV2neo, and presented as 2, 1, or 11 as described in Fig. 1. For transformation results
shown in B, numerical values are also shown in parentheses as the percentage of p185neu.Chen et al. Transmembrane Sequences for Receptor Activation 627
mutant CONS.AE2 (Fig. 6 A). The active mutant has a back-
ground CONS.C motif of [VVVEVVV], whereas the in-
active mutant has a background CONS.A motif of [VVV-
EVVA]; these sequences differ only by the Val®Ala
substitution in the last position of the repeat motif. This
suggests that the ability of a single Glu residue to activate
a particular transmembrane domain, as occurs in the case
of p185neu, may be critically dependent upon other specific
details of the transmembrane domain that are not immedi-
ately obvious. These results may help to explain the nega-
tive results of earlier studies in which repositioning of the
Glu664 residue to other locations in the transmembrane do-
main did not result in transformation (Cao et al., 1992).
Kinase Activity of Mutants
Transformation by the neu oncogene is dependent upon
p185neu having a functional kinase domain, and p185neu ex-
hibits increased turnover, autophosphorylation, tyrosine
phosphorylation of intracellular substrates, and activation
of PLC-g (Bargmann and Weinberg, 1988a; Stern et al.,
1988; Weiner et al., 1989a,b; Peles et al., 1991; Cao et al.,
1992; Brown et al., 1994). Moreover, transformation and
SH2-dependent signaling by p185neu requires intermolecu-
lar receptor association that is mediated by the transmem-
brane domain, as demonstrated by functional complementa-
tion between truncated kinase-active p185neu and full-length
kinase-inactive p185neu (Qian et al., 1994, 1995). Another
indication of receptor dimerization and aggregation is pro-
vided by measurement of ligand-binding using chimeras
consisting of the ligand-binding domain of EGFR substi-
tuted into either p185c-neu or p185neu; the Val®Glu muta-
tion in the transmembrane domain of such EGFR/Neu
chimeras results in the conversion of low-affinity ligand-
binding sites into high-affinity binding sites, consistent
with an oligomerized state of the oncogenic receptor
(Ben-Levy et al., 1992).
To confirm kinase activation of the mutants described
here, selected mutants were examined for receptor activa-
tion using an immunoprecipitation/kinase assay of trans-
fected Cos-1 cells. As shown in Fig. 7 A, p185neu exhibited
approximately threefold greater autophosphorylation than
Figure 7. Immunoprecipitation/kinase assay of consensus mu-
tants. Lysates from transfected cells, labeled metabolically with
[35S]Cys and [35S]Met, were subjected to immunoprecipitation us-
ing monoclonal antibody 7.16.4, as described in Materials and
Methods. (A) Kinase assay. Immunoprecipitated lysates were
subjected to in vitro kinase reactions using g-[32P]ATP. 32P-labeled
proteins were detected by SDS-PAGE and autoradiography. Ex-
posure time was 21 h. (B) Expression. To demonstrate equivalent
levels of protein expression for different mutants, identical ali-
quots of immunoprecipitated lysates as used in A were analyzed
by SDS-PAGE followed by fluorography to detect 35S-labeled
proteins. Exposure time was 3 d. The samples shown in lanes 2, 4,
and 6 represent nontransforming clones, while the samples shown
in lanes 3, 5, and 7 represent transforming derivatives. Lane 1,
mock; lane 2, p185c-neu; lane 3, p185neu; lane 4, CONS.CE®V; lane
5, CONS.C; lane 6, CONS.AE®S; lane 7, CONS.AE®Q.
Figure 8. Detection of phosphotyrosine in immunoprecipitated
receptors. Lysates were prepared from transfected cells and were
subjected to immunoprecipitation using monoclonal antibody
7.16.4, as described in Materials and Methods. Immunoprecipi-
tated lysates were analyzed on a 4–12% gradient gel under reduc-
ing conditions, transferred to nitrocellulose, probed with mono-
clonal phosphotyrosine antiserum 4G10 (A) or with polyclonal
p185c-neu C-18 antiserum (B), and specific proteins were detected
by ECL. The samples shown in lanes 2, 4, and 6 represent non-
transforming clones, while the samples shown in lanes 3, 5, and 7
represent transforming derivatives. A shows detection of phos-
photyrosine, and B shows detection of receptor expression. Sam-
ples are: lane 1, mock; lane 2, p185c-neu; lane 3, p185neu; lane 4,
CONS.CE®V; lane 5, CONS.C; lane 6, CONS.AE®S; lane 7,
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p185c-neu (lanes 3 and 2, respectively). The mutants
CONS.CE®V and CONS.C were examined, as they repre-
sent an interesting pair of closely related mutants. The first
of these is inactive in transformation assays, whereas the
latter mutant is active. In the immunoprecipitation/kinase
assay, the biologically active mutant CONS.C exhibited a
similar increase in autophosphorylation compared with
the inactive receptor CONS.CE®V (lanes 5 and 4, respec-
tively). We also examined another pair of closely related
mutants, CONS.AE®S and CONS.AE®Q, where once again
the first mutant is inactive in transformation assays, but
the latter mutant is active. Once again, in the immunopre-
cipitation/kinase assay, the biologically active mutant
CONS.AE®Q exhibited an increase in autophosphoryla-
tion compared with the inactive mutant CONS.AE®S
(lanes  7 and 6, respectively). In this experiment, similar
levels of protein expression were achieved for p185c-neu,
p185neu, and the various mutants examined, as demon-
strated by 35S-metabolically labeled/immunoprecipitated
proteins from the same lysates (Fig. 7 B). Thus, consistent
with prior experimental results from other laboratories
(Bargmann and Weinberg, 1988a; Stern et al., 1988; Weiner
et al., 1989a,b; Cao et al., 1992), biologically active deriva-
tives constructed in this work exhibited increased levels of
kinase activity, as determined by receptor autophosphory-
lation in immunoprecipitation/kinase assays.
Immunoprecipitated samples were also examined for
the presence of phosphotyrosine by immunoblotting. Fig.
8 A demonstrates that two transforming mutants, CONS.C
(lane 5) and CONS.AE®Q (lane 7), exhibit significant in-
corporation of phosphotyrosine into immunoprecipitated
receptors, as did the positive control, p185neu (lane 3).
Little or no phosphotyrosine was associated with the
nontransforming mutants, CONS.CE®V (lane 4) and
CONS.AE®S (lane 6), or with the nontransforming con-
trol, p185c-neu (lane 2). As a control for receptor expression
levels, B demonstrates approximately equivalent levels of
receptor expression, determined by immunoblotting using
polyclonal p185c-neu C-18 antiserum.
These same mutants were also examined for receptor
dimerization using gradient gel electrophoresis under non-
reducing conditions (Weiner et al., 1989b; Burke et al.,
1997). Fig. 9 B presents these results, while the same ly-
sates were also analyzed under reducing conditions as a
control, shown in A. Two transforming mutants, CONS.C
(lane 5) and CONS.AE®Q (lane 7), exhibited significant
bands of dimeric receptors, as did the positive control,
p185neu (lane 3). Importantly, no dimerization was ob-
served for the nontransforming mutants analyzed here,
CONS.CE®V (lane 4) and CONS.AE®S (lane 6), or for the
nontransforming control, p185c-neu (lane 2). The ability to
detect receptor dimerization for the transforming mutants,
but not for the biologically inactive mutants, indicates that
the consensus sequences described here promote receptor
dimerization, and that in this respect they are similar to
the parental transforming clone, p185neu.
Discussion
Function of the Transmembrane Domain
The results presented here demonstrate that activation of
p185c-neu can be achieved by a transmembrane domain
with very little sequence specificity. Glu residues in the ap-
propriate positions of a simplified transmembrane do-
main, such as [VVVEVVV]n, lead to receptor activation as
demonstrated by biological transformation (Fig. 3), in-
creased kinase activity (Fig. 7), increased incorporation of
phosphotyrosine (Fig. 8), and receptor dimerization (Fig.
9). Receptor activation is conferred by as few as one or as
many as four Glu residues within some of these repeats.
Moreover, a periodic heptad spacing seems to be critical
Figure 9. Dimerization as-
say of consensus mutants.
Lysates were prepared from
transfected cells in RIPA
containing 10 mM iodoaceta-
mide and were subjected to
immunoprecipitation using
monoclonal antibody 7.16.4,
as described in Materials and
Methods. Immunoprecipi-
tated lysates were analyzed
on a 4–12% gradient gel and
transferred to nitrocellulose,
probed with a polyclonal
p185c-neu C-18 antiserum, and
specific proteins were de-
tected by ECL. The samples
shown in lanes 2, 4, and 6
represent nontransforming
clones, while the samples
shown in lanes 3, 5, and 7
represent transforming de-
rivatives. A shows samples
analyzed under reducing gel
electrophoresis conditions.
B shows samples analyzed under nonreducing gel electrophoresis conditions. Samples are: Lane 1, mock; lane 2, p185c-neu; lane 3,
p185neu; lane 4, CONS.CE®V; lane 5, CONS.C; lane 6, CONS.AE®S; lane 7, CONS.AE®Q.Chen et al. Transmembrane Sequences for Receptor Activation 629
for activation; this was demonstrated by systematically
varying the spacing between two Glu residues from two to
eight, with only the heptad spacing resulting in activation
(Fig. 5 B). Thus, an apparently complex system can be
reduced to a repeated sequence motif. Furthermore, in
these simplified transmembrane domains, Gln is able to
substitute efficiently for Glu, as shown by the mutant
CONS.AE®Q. This is consistent with previous observations
(Bargmann and Weinberg, 1988b) that Gln, but not Ser,
Lys, or Asp, was able to substitute for Glu at position 664
in receptor activation (Fig. 3).
From the transforming isolates of degenerate Pool 1, it
is clear that the location of Glu at position 664 is not criti-
cal for activation (Fig. 1), in contrast to prior results sug-
gesting that the primary structure around Glu664 plays an
important role. For instance, mutants with Glu663 or Glu665
were inactive (Bargmann and Weinberg, 1988b). More re-
cently, Cao et al. (1992) analyzed the requirements for ac-
tivation of the p185neu transmembrane domain; all of their
transforming mutants retained Glu at position 664, and a
mutant (designated lil670VEG) with the motif VEG seven
residues COOH-terminal, was nontransforming.
Our isolation of the transforming mutants DEG.2, DEG.3,
DEG.4, and DEG.5, all of which lack a Glu at position
664, would suggest that there exists considerable flexibility
with regard to the allowed placement of the Glu residue(s)
that may mediate activation. The isolation of these trans-
forming mutants also demonstrates that the construction
of a degenerate pool of oligonucleotides encoding trans-
membrane domains provides a powerful approach to iden-
tifying and isolating those rare sequences that may allow
receptor activation.
Our data show that activation of p185c-neu can be medi-
ated by Glu residues spaced seven amino acids apart in a
repeating heptad. Analysis of the sequences of the isolates
from Pool 1 (Fig. 1) is consistent with this proposal. Most
of the transforming isolates contain Glu residues sepa-
rated by multiples of seven amino acids. In the nontrans-
forming isolate, DEG.6, which was expressed at the cell
surface (in contrast to DEG.7 and DEG.10), there are Glu
residues spaced seven amino acids apart, but there is also a
Glu that does not follow that pattern. This may suggest
that the presence of a Glu in a nonheptad motif may cause
a disruption in the interaction between receptor molecules
that prevents transforming ability, although it is difficult to
infer absolute rules because of the other sequence varia-
tions exhibited by the DEG mutants.
The Val®Glu mutation that activates p185neu is also ac-
tivating when introduced into the corresponding position
of the Drosophila EGFR homologue (DER), resulting in
increased kinase activity (Wides et al., 1990). Although it
was initially reported that the corresponding Val627®Glu
mutation does not activate the human EGFR transmem-
brane domain (Kashles et al., 1988), a more recent study
suggests that this mutation is activating (Beguinot et al.,
1995). Additionally, a Val®Glu mutation at position 659
in c-erbB-2, the human Neu homologue that is overex-
pressed in many breast cancers, results in elevated tyrosine
kinase activity (Segatto et al., 1988). These examples pro-
vide further evidence for activation of EGFR family mem-
bers by appropriate introduction of a strongly polar resi-
due in their transmembrane domains.
The hydrophobic environment of the membrane creates
an energetic need to shield polar side chains such as that of
Glu (even if uncharged), which can be accomplished by
appropriate hydrogen bonding. Previously, it was pro-
posed that there may be a requirement for Ala661 in
p185neu to allow hydrogen bonding between the Glu664 side
chain of one receptor with the carbonyl oxygen of Ala661 in
the other. There is clearly no strict requirement for Ala at
position 661, however, as shown by the fact that Val is tol-
erated at position 661 in many of the biologically active
mutants described here. The presence of the branched side
chain at Val661, which might interfere with side chain–
backbone hydrogen bonding, argues against this model
but does not exclude it. More likely, however, would be a
model of side chain–side chain hydrogen bonding between
the Glu of one subunit with the corresponding Glu of the
other subunit. The choice between these two models will
require further biophysical characterization. While the re-
sults presented in this work are certainly consistent with a
coiled-coil arrangement for the interacting transmem-
brane domains of p185neu, other structural models cannot
be excluded at the present time, such as one proposed for
the homodimerizing transmembrane domain of glyco-
phorin A (Lemmon et al., 1992; Treutlein et al., 1992).
Relevance of p185neu Activation to Other Systems
As summarized in Fig. 10, prior studies have demonstrated
that substitutions at position 664 of p185neu exhibit the fol-
lowing pattern of biological activity: Glu, Gln . Asp, Tyr
@ Val, Lys, Gly, His (Bargmann and Weinberg, 1988b).
These results are generally consistent with a role of polar
or hydrophilic residues in promoting activation, although
the failure of Lys and His to allow for activation remains
Figure 10. Oncoproteins and receptors activated by mutations in
the transmembrane domain. Amino acids are shown that allow
activation of p185c-neu when substituted at residue 664, activation
of BPV-E5 when substituted at residue 17, and activation of
FGFR3 when substituted at residue 380, as discussed in the text.
Those substitutions that allow activation in these three different
systems share the property that they are strongly polar in an oth-
erwise hydrophobic membrane environment, and thus share the
ability to participate in hydrogen bond formation that may stabi-
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to be explained. The E5 oncoprotein of bovine papilloma
virus (BPV) provides another example of the importance
of the transmembrane domain for activation, since this 44-
residue integral membrane protein requires dimerization
and disulfide bond formation for its biological activity
(Horwitz et al., 1988, 1989; Goldstein et al., 1992). A key
requirement of its hydrophobic transmembrane domain is
the presence of Gln17, which appears to participate in in-
terhelical hydrogen bonding and may be substituted by ei-
ther Glu or Lys, and to a lesser extent by His (Meyer et al.,
1994). Significantly, the transmembrane domain of E5 can
be largely replaced by the membrane-spanning region
from activated p185neu (Meyer et al., 1994).
The transmembrane domain of the T cell receptor a
chain (TCRa) also appears to play a key role in complex
formation between TCRa and the CD3g chain, mediated
by two basic residues in the TCRa transmembrane do-
main (Cosson et al., 1991). As another relevant example,
the basic residues within the transmembrane domain of
gp41 in human immunodeficiency virus type 1 (HIV-1)
have been suggested to play a role in oligomerization of
the HIV-1 envelope glycoprotein (Owens et al., 1994).
Transmembrane Domain Mutations in Human 
Developmental Syndromes
Transmembrane-mediated receptor activation clearly plays
a fundamental role in several human developmental syn-
dromes. Achondroplasia, the most common genetic form
of human dwarfism, results from a single amino acid change
in the transmembrane domain of FGFR3, Gly380®Arg
(Rousseau et al., 1994; Shiang et al., 1994). This mutation
results in constitutive activation of FGFR3, leading to ab-
normal development at the growth plate of long bones
(Webster and Donoghue, 1996). As depicted in Fig. 10, we
have previously demonstrated that mutations at residue
380 of FGFR3 exhibit the following pattern of activation:
Arg, Glu, Asp . Gln, His @ Lys (Webster and Donoghue,
1996). Recently, Meyers et al. (1995) characterized an au-
tosomal dominant mutation in FGFR3 that is manifested
as two distinct developmental syndromes presented to-
gether: first, acanthosis nigricans, a hyperplastic epithelial
proliferation syndrome resulting in thickened hyperpig-
mented skin; and second, Crouzon Syndrome, character-
ized by craniosynostosis or premature fusion of the cranial
sutures, resulting in cranial malformation and ocular prop-
tosis. The mutation responsible for these developmental
anomalies maps to the transmembrane domain of FGFR3
and, surprisingly, involves a single substitution mutation
creating a Glu residue (Ala391®Glu). Using FGFR3/Neu
chimeras, we have recently demonstrated that the Ala391®
Glu mutation also leads to constitutive receptor activation
(Webster, M.K., and D.J. Donoghue, unpublished data).
It is clear that transmembrane domains play a more sub-
stantial role than serving as structural elements for mem-
brane anchoring. The examples discussed above under-
score the importance of understanding the molecular
details of activating mutations in the transmembrane do-
mains of receptors. The principles elucidated here are
likely to be generally relevant to understanding activation
and signal transduction by other receptor tyrosine kinases
in addition to p185neu.
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